ForceClouds Secures Over RMB 40 Million in New Funding to Develop Next-Gen AI-Powered Life Sciences Cloud Solutions

VCBeat (WeChat ID: vcbeat) reports. Recently, CloudPower Software, a cloud solutions provider in the life sciences sector, announced the completion of a new round of financing totaling RMB 20 million plus USD 3.5 million. The round was led by Oriental Fortune Capital, with participation from Blue Lake Capital and existing shareholder STIC Capital (formerly Fidelity Asia Ventures). The financing was finalized in early 2018, and all funds have now been received.

Yunshi Software is a SaaS provider specializing in cloud solutions for the life sciences sector. Dedicated to leveraging advanced cloud platforms, big data analytics, and artificial intelligence technologies, it delivers simple, secure, efficient, and compliant cloud-based solutions for automated information management to companies in the pharmaceuticals, medical devices, animal health, crop science, and nutrition and wellness industries, as well as clinical-related institutions such as CROs and hospitals.

It is understood that the three major product suites launched by Yunshi Software include the Sales Management Business Suite, the Clinical Trials Suite, and the Big Data and Artificial Intelligence Suite.

Among these, the Sales Management Business Suite is the only solution in China dedicated to providing end-to-end digitalization of Sales Force Effectiveness (SFE) management for the life sciences sector. It encompasses solutions such as healthcare master data management, structural metric management, CRM, incentive compensation management, BI business reporting, corporate internal training management, and channel optimization management. The suite primarily helps enterprise users enhance precision marketing capabilities within the sales process, thereby driving improved sales performance.

The clinical trial suite primarily offers solutions such as Electronic Data Capture (EDC) and Clinical Trial Management Systems (CTMS), enabling enterprise users to maintain end-to-end control of trials through data management during the clinical trial phase. Additionally, this suite extends into real-world studies to support medical research.

Yunshi Software closely integrates cutting-edge international artificial intelligence and big data analytics technologies with the pharmaceutical industry, applying them in areas such as intelligent diagnostics and drug sales forecasting. This approach enhances the information management capabilities of pharmaceutical enterprise clients, ultimately strengthening their core competitiveness.

Currently, CloudSine Software serves clients including Fortune 500 companies such as AstraZeneca, Bayer, and Wyeth Nutrition; leading multinational corporations in specialized fields such as Eisai, Takeda Pharmaceutical, Mundipharma, and Dentsply Sirona; domestic industry leaders such as China Resources Double-Crane, Hisun Pfizer (formerly Hisun-Pfizer), and Salubris; as well as CRO companies such as Anhui Wanbang and Dishizhi Consulting. CloudSine Software’s products and services have received positive feedback from more than 50,000 enterprise users.

Zhang Yingnan, Founder and CEO of Yunshi Software, stated that in 2018, the company would focus on three key strategic objectives. First, in the area of its sales management business suite, Yunshi Software will continue to increase R&D and marketing investments to consolidate its existing leading advantage and widen the gap with competitors. Second, the company will further ramp up R&D investment in its clinical trial suite, leveraging AI technology to create next-generation intelligent clinical trial management products. Finally, Yunshi Software will accelerate the commercialization of AI-assisted drug discovery products incubated by the “Cornell-Yunshi Medical Artificial Intelligence Laboratory,” thereby advancing the company’s internationalization strategy.

Regarding the first two strategic objectives, Zhang Yingnan stated that the management team is fully confident in achieving them. A key factor behind this confidence is Yunshi Software’s continued strong performance growth in 2017, with an increasing number of large and medium-sized clients from the Fortune Global 500 and China Top 100 choosing its products and services. These clients include renowned pharmaceutical companies and multinational corporations such as AstraZeneca, Bayer, Green Valley Pharmaceutical, and China Resources Double-Crane Pharmaceutical. It is reported that Zhang Yingnan’s primary focus in 2018 will be to rapidly commercialize the AI-assisted drug R&D product developed in collaboration with Cornell University in the United States. He is currently establishing a New York branch office and diligently building a consulting team targeting leading global pharmaceutical companies in this new product domain. In the field of AI-assisted drug research and development, Yunshi Software already boasts a world-class expert team and absolutely leading technological R&D capabilities.

Currently, Yunshi Software has developed the world’s first AI-driven drug discovery engine. This technology is dedicated to significantly enhancing the efficiency of new drug discovery. It not only shortens the drug development cycle but also leverages machine learning to uncover relationships among drugs, between drugs and diseases, and between drugs and genes—associations that are difficult to identify through conventional methods—while also elucidating their underlying logical connections. Currently, this technology holds a leading position in both domestic and international healthcare industries.

Chen Liwei, Partner at Oriental Fortune Capital, the lead investor in this round, stated, “We place great emphasis on Yunshi Software’s deep technical foundations and accumulated expertise. As the saying goes, ‘a nine-story tower begins with a pile of earth.’ Yunshi Software has established a clear technological leadership in big data and artificial intelligence, building a unique competitive moat. The life sciences sector is currently experiencing robust growth, and AI represents the forefront of technological innovation. Yunshi Software has achieved a seamless integration of these two domains. Furthermore, its team members possess extensive experience and strong synergy in both the life sciences and SaaS sectors. Their products have gained widespread recognition and adoption among Fortune 500 companies as well as large and medium-sized enterprises in China, and their business model is highly transparent. We are confident that Yunshi Software is poised to become the most prominent rising star in the life sciences industry.”